CytoMed Therapeutics (GDTC) Assets Average (2023 - 2025)
CytoMed Therapeutics (GDTC) posted Assets Average of $7.3 million for Q4 2025, down 8.84% sequentially from $8.0 million in Q2 2025, and down 21.43% YoY from $9.2 million in Q4 2024.
CytoMed Therapeutics (GDTC) Assets Average (2023 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Assets Average for 3 years, with the latest figure at $7.3 million in Q4 2025.
- Quarterly Assets Average fell 21.43% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (down 21.43% YoY) and the FY2025 annual result came in at $6.9 million, down 17.93% from the prior year.
- Assets Average slipped to $7.3 million in Q4 2025 per GDTC's latest filing, from $8.0 million in the prior quarter.
- Over five years, Assets Average peaked at $11.5 million in Q4 2023 and troughed at $7.3 million in Q4 2025.
- A 3-year average of $9.1 million and a median of $9.0 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average rose 13.52% in 2024, then dropped 21.43% in 2025.
- Over 3 years, Assets Average stood at $11.5 million in 2023, then dropped by 19.92% to $9.2 million in 2024, then dropped by 21.43% to $7.3 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $7.3 million, $8.0 million, and $9.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 19.82 Bn |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | 7.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.26 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Dec 31, 2024 | 9.24 Mn |
| Jun 30, 2024 | 10.04 Mn |
| Dec 31, 2023 | 11.54 Mn |
| Jun 30, 2023 | 8.84 Mn |